Sigyn Therapeutics, Inc.
SIGY- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001642159
No open-market purchases or sales by Sigyn Therapeutics, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.35K in total; no superinvestor holds it.
Holders of 5% or more of SIGY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Sigyn Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Brio Capital Master Fund Ltd. | 13G/A | 9.99%160.5K shares | 0.00 ppfrom 9.99% | Jan 27, 20215 filings | Jan 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Sigyn Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jan 14, 20269:08 AM ET | Brio Capital Master Fund Ltd.and 1 other | 13G/A | 9.99%160.5K shares | 0.00 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 14, 20255:38 PM ET | Brio Capital Master Fund Ltd.and 1 other | 13G/A | 9.99%158.9K shares | – | Nov 19, 2024 | SEC |
| Feb 8, 2024 | Brio Capital Master Fund Ltd. | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Brio Capital Master Fund Ltd. | 13G/AOld format | – | – | – | SEC |
| Jan 27, 2021 | Brio Capital Master Fund Ltd. | 13G/AOld format | – | – | – | SEC |
| Jan 14, 20213:49 PM ET | Alpha Capital Anstalt | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Sigyn Therapeutics, Inc. shares.
No Form 144 notices for Sigyn Therapeutics, Inc. are on file.